Combination therapy with targeted and anti-angiogenic agents in second-line nonsmall cell lung cancer
| First author, year [ref.] | Phase | Patients | Arms | PFS months | p-value | OS months | p-value | Response rate % | p-value |
| Herbst, 2011 [58] | III | 636 | Erlotinib + bevacizumab | 3.4 | 9.2 | 13 | |||
| Erlotinib + placebo | 1.7 | 9.3 | 6 | ||||||
| Scagliotti, 2012 [60] | III | 960 | Erlotinib + sunitinib | 3.6 | 0.0023 | 9.0 | 0.1388 | 10.6 | 0.0471 |
| Erlotinib + placebo | 2.0 | 8.5 | 6.9 | ||||||
| Spigel, 2011 [62] | II | 168 | Erlotinib + sorafenib | 3.38 | 0.196 | 7.62 | 0.29 | 8.0 | 0.56 |
| Erlotinib + placebo | 1.94 | 7.23 | 11.0 | ||||||
| Besse, 2013 [66] | II | 133 | Erlotinib + everolimus | 2.9 | 0.228 | 9.1 | 12.1 | ||
| Erlotinib | 2.0 | 9.7 | 10.4 | ||||||
| Price, 2010 [65] | II | 31 | Gefitinib + everolimus | 11.0 | 9.6 | ||||
| Sequist, 2011 [68] | II | 167 | Erlotinib + tivantinib | 3.8 | 0.24 | 8.5 | 0.47 | 10 | ns |
| Erlotinib + placebo | 2.3 | 6.9 | 7 | ||||||
| Ramalingam, 2011 [70] | II | 172 | Erlotinib + R1507 weekly | 1.9 | 8.1 | 8.8 | |||
| Erlotinib + R1507 every 3 weeks | 2.7 | 0.67 | 8.1 | 0.48 | 7.0 | ||||
| Erlotinib + placebo | 1.5 | 0.73 | 12.1 | 0.04 | 8.8 |
Data are presented as n, unless otherwise stated. PFS: progression-free survival; OS: overall survival; ns: non significant.